Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive Officer

Published: Tuesday, April 16, 2013
Last Updated: Tuesday, April 16, 2013
Bookmark and Share
Former SeraCare CEO and Millipore executive to guide strategic direction of life sciences services and technology company.

Aushon BioSystems announced the appointment of Susan Vogt as chief executive officer. Vogt brings more than 30 years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics markets to her new role. Founder and former CEO Pete Honkanen will assume the role of chief operating officer and continue as a board director.

Vogt's experience includes leadership roles at both small and large private and public companies. Most recently, Vogt led the turnaround of diagnostics reagents company SeraCare Life Sciences as president and CEO, where she successfully re-listed the company on NASDAQ and returned the company to growth and profitability. Previously, Vogt held numerous senior level positions at Millipore Corporation, including corporate officer and president of the company’s biopharmaceutical division. She currently serves as non-executive director of TAP BioSystems, and has previously served on the board of directors and advisory boards of a number of other private and publicly-held companies. Vogt holds an MBA from Boston University and a BA from Brown University.

“With sound technology, an elegant, easy-to-use platform and a strong customer base, Aushon is well-positioned to lead the market as the demand for multiplexing in the life sciences continues to grow,” said Vogt. “Our technology enables research that’s critical to the development of both therapeutics and diagnostics, and I look forward to driving the company’s future growth.”

Aushon provides a suite of multiplex immunoassay products and services for the discovery and development of the biomarkers necessary to enable personalized medicine innovation. Multiplexing involves simultaneously measuring and comparing multiple proteins – an improvement over today’s standard which measures one at a time. Fueled by a growing market for multiplexing, Aushon recently announced an anticipated 30 percent year-over-year revenue growth in 2013 and added Thomas Mac Mahon, former president and CEO of Laboratory Corporation of America® Holdings (LabCorp®), to its board of directors.

“Susan is joining Aushon at an exciting time, as we’re expanding to meet increasing demand for our technologies and services by pharmaceutical, biotech and other life sciences research organizations,” said Honkanen. “Her appointment is further evidence of Aushon’s momentum in helping our customers drive the development of new tests and therapies, enabling personalized medicine and, ultimately, better healthcare for patients.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine
Adds former LabCorp leader Thomas Mac Mahon to board of directors, expects further growth in 2013.
Wednesday, February 27, 2013
Aushon Appoint New Chief Scientific Officer
Aushon, a provider of advanced microarray products and laboratory services for biomarker discovery, have announced that Sven Beushausen, Ph.D., has been appointed to the position of Chief Scientific Officer.
Wednesday, November 24, 2010
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!